Guillain Barré syndrome and SARS-CoV-2 infection: Report of two cases in Peru.
DOI:
https://doi.org/10.20453/rnp.v84i1.3938Keywords:
COVID-19, Acute Inflammatory Polyneuropathy, Guillain Barré syndrome.Abstract
Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, shows mainly clinical manifestations at the respiratory level. It can affect, however, other organs and systems, including the central nervous system, generating neurological manifestations that include the Guillain Barré Syndrome (GBS). We present the cases of two male patients, aged 35 and 46, with GBS, one classified as AMAN and the other as AIDP. Both patients showed positive serology for SARS-CoV-2 and reported respiratory symptoms prior to the weakness condition. RT-PCR in pharyngeal secretion and CSF was negative in both cases. The infection by SARS-CoV-2 was confirmed by the total antibody test in serum through a positive CLIA immunoassay, positive for IgG in the two cases. The characteristics of the cases support a possible postinfectious relationship between SARS-CoV-2 and GBS, and open as well the possibility that despite being asymptomatic or having mild respiratory symptoms, some patients may develop post- infectious complications such as GBS.
Downloads
References
Deng S-Q, Peng H-J. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med. 2020;9(2):575. doi:10.3390/jcm9020575
Rashid ZZ, Othman SN, Samat MNA, Kalsom U, Ken WK. Diagnostic performance of COVID-19 serology assays. Malays J Pathol. 2020;42(1):13-21.
Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol. 2020;70(9):311–22. doi:10.33588/rn.7009.2020179
Donofrio PD. Guillain-Barré Syndrome. Contin Minneap Minn. 2017;23(5):1295–309. doi: 10.1212/ con.0000000000000513
Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. Clin Neurosci. 2020;76:233-235. doi: 10.1016/j. jocn.2020.04.062
El Otmani H, El Moutawakil B, Rafai M-A, El Benna N, El Kettani C, Soussi M, et al. Covid-19 and Guillain-Barré syndrome: More than a coincidence! Rev Neurol (Paris). 2020;176(6):518-519. doi: 10.1016/j.neurol.2020.04.007
Camdessanche J, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. COVID-19 may induce Guillain–Barré syndrome. Rev Neurol (Paris). 2020; 176(6): 516-518. doi: 10.1016/j. neurol.2020.04.003
Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: A systematic review and current update. Acta Neurol Scand. 2020;142(1):14–22. doi:10.1111/ane.13266
Coen M, Jeanson G, Culebras-Almeida LA, Hübers A, Stierlin F, Najjar I, et al. Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. Brain Behav Immun. 2020;87:111-112. doi: 10.1016/j. bbi.2020.04.074
Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 2020; 382(26):2574-2576. doi: 10.1056/ NEJMc200919
Finsterer J, Scorza FA, Ghosh R. COVID-19 polyradiculitis in 24 patients without SARS-CoV-2 in the cerebro-spinal fluid. J Med Virol. 2020;10.1002/ jmv.26121. doi: 10.1002/jmv.2612
Trujillo LM, Valenzuela SN, von Oetinger A, Relación entre COVID-19 y síndrome de Guillain- Barré en adultos. Revisión sistemática. Neurologia. 2020;35(9):646-654. doi: 10.1016/j.nrl.2020.07.004
Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95(5): e601-e605. doi: 10.1212/WNL.0000000000009619
RNP is distributed under a 